<?xml version="1.0" encoding="UTF-8"?>
<p id="p0265">In Guan et al.’s study
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> of 173 severe COVID-19 cases, 58 patients (33.4%) received intravenous immunoglobulin treatment (IVIG). IVIG was considered as a potential therapy for immunologic injury in COVID-19 in clinical practice because of its antiinflammatory action in treating conditions such as hemophagocytic lymphohistiocytosis and cytokine storm. Similarly, two reviews recommended IVIG based on mechanisms of SARS-CoV-2–mediated inflammatory responses.
 <xref rid="bib62" ref-type="bibr">
  <sup>62</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib63" ref-type="bibr">
  <sup>63</sup>
 </xref> However, further investigation and more clinical studies are needed.
</p>
